文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

低剂量白介素-2在11种自身免疫病中的免疫学与临床效应:单中心开放临床试验

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
PubMed 文献 · Ann Rheum Dis · 2018-11-24

结果显示ld-IL2耐受性良好,所有患者均出现Treg选择性扩增和活化,而无效应T细胞活化,并观察到潜在临床疗效迹象。

要点

  • 低剂量IL-2在11种自身免疫病中耐受性良好,不受合并治疗影响。
  • 所有患者均出现Treg选择性扩增和活化,无效应T细胞活化。
  • 观察到潜在临床疗效迹象,支持开展II期疗效试验。

核心结论

  • 低剂量IL-2选择性激活和扩增Treg,在多种疾病及合并治疗中安全,初步疗效迹象支持开展II期试验。

研究设计与样本

  • 前瞻性、开放标签、I-IIa期研究,纳入46例11种轻中度自身免疫病患者。

主要发现

  • ld-IL2耐受性良好,无论疾病类型和合并治疗如何。
  • 全面免疫监测显示所有患者Treg特异性扩增和活化,无效应T细胞活化。
  • 观察到潜在临床疗效迹象。

临床怎么用

  • 该方案支持在多种自身免疫和炎症性疾病中启动ld-IL2的II期疗效试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential. AIM: We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases. METHODS: We performed a prospective, open-label, phase I-IIa study in 46 patients with a mild to moderate form of either rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet's disease, granulomatosis with polyangiitis, Takayasu's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis and sclerosing cholangitis. They all received ld-IL2 (1 million IU/day) for 5 days, followed by fortnightly injections for 6 months. Patients were evaluated by deep immunomonitoring and clinical evaluation. RESULTS: ld-IL2 was well tolerated whatever the disease and the concomitant treatments. Thorough supervised and unsupervised immunomonitoring demonstrated specific Treg expansion and activation in all patients, without effector T cell activation. Indication of potential clinical efficacy was observed. CONCLUSION: The dose of IL-2 and treatment scheme used selectively activate and expand Tregs and are safe across different diseases and concomitant treatments. This and preliminary indications of clinical efficacy should licence the launch of phase II efficacy trial of ld-IL2 in various autoimmune and inflammatory diseases. TRIAL REGISTRATION NUMBER: NCT01988506.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2018. PMID: 30472651. doi:10.1136/annrheumdis-2018-214229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。